RASA1 / NF1 -Mutant Lung Cancer: Racing to the Clinic?

Although mutation of NF1 has been described in non-small cell lung cancer (NSCLC), co-mutation with RASA1 , another Ras-GTPase activating protein (RasGAP), defines a novel genetically defined subclass of NSCLC. RASA1 / NF1 -mutant cell lines are highly sensitive to MEK inhibitors, warranting clinical evaluation of MAPK inhibition in this subclass of patients. Clin Cancer Res; 24(6); 1243-5. ©2018 AACR See related article by Hayashi et al., p. 1436 .